Skip to content

News & Resources

Featured Stories

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA Read More
Posted on 11.18.24
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
San Francisco Business Times
Posted on 10.11.24
Siren CEO & Founder Dr. Nicole Paulk honored as one of the Most Influential Women in Bay Area Business
Posted on 9.17.24
AAV downstream challenges: expert insights
Posted on 8.15.24
Siren Biotechnology Wins Beckman Coulter SPRI Grants for Genomic Research
Posted on 8.9.24
Unveiling the critical pathways in AAV potency evaluation and future trends in gene therapy
Posted on 7.26.24
BioBreakthroughs: Gene Therapy Innovation
Posted on 6.28.24
Building A Universal AAV For Cancer
Posted on 6.4.24
MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant
Posted on 4.27.24
How Viral Gene Therapy will Revolutionize Cancer Treatment
Posted on 4.3.24
Biopharma’s AI Revolution | The Future of Medicine